Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTCs in Japan

This article was originally published in The Tan Sheet

Executive Summary

Over-the-counter drugs may be sold in Japan when pharmacists are not present in stores, provided that a staff member at the retail outlet consults with an on-call pharmacist through videophone, the Japanese Ministry of Health, Labour & Welfare decides in a Jan. 22 report. The "deregulation" will result in the late-night sale of OTCs from 10 pm to 6 am, when pharmacists are not on staff, according to a spokesperson from the Japanese Embassy. In a recent letter, CHPA urged the U.S. Trade Representative to consider distribution restrictions on nonprescription drugs in Japan as a trade barrier to entry for American firms (1"The Tan Sheet" Jan. 5, 2004, p. 10)...

You may also be interested in...



Japanese Ministry Of Health Looks To Revise OTC Retailing Regulations

Risk-based classification for OTC drugs in Japan is an issue that will figure prominently during a Nov. 15 meeting of a Working Group established by the government's "Task Force to Study Pharmaceutical Retailing.

Japan OTC Retail, Advertising Barriers Should Be Addressed By USTR – CHPA

The Consumer Healthcare Products Association urges the U.S. Trade Representative in recent comments "to draw attention to OTC medicine distribution restrictions" in Japan as an "indirect barrier to market entry" in its upcoming annual report on foreign trade barriers

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096408

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel